Abstract Flow accelerated corrosion (FAC) is a steel degradation that occurs in heat recovery steam generators in the power industry. The mechanism of this corrosion comprises an electrochemical dissolution of the semi-protective magnetite layer (Fe3O4) that is formed within the pipes employed in the boilers. The FAC is influenced by different factors such as fluid velocity, pH and dissolved oxygen concentration. In this context, Rotating Cage tests were used to evaluate the influence of pH and dissolved oxygen content on FAC of A210, P11 and P22 steels. General corrosion was lower for P11 and P22 steels, an effect consistent with the presence of chromium in their compositions. General corrosion was most critical at pH 8.5. The corrosion intensity decreased for the three steels when the dissolved oxygen concentration increased, at 2 m/s. This behavior is coherent considering the most effective precipitation of Fe2O3 inside the pores of the Fe3O4 layer in a more oxidizing environment. For 3 m/s, the corrosion intensity increased for both materials when oxygen increased, showing the shear stress effect. These behaviors were more significant at pH 8.5. About pitting corrosion, the analyzes show localized attack in the majority of coupons, however with very low number of pits.

This is the first record on the invasion of the Neotropical brown stink bug, Euschistus heros (F.) in Paraná County (latitude 31º 51' 9.6" S, longitude 60º 32' 11.2" W), Entre Ríos province, Argentina. Five adults were intercepted in 2009/2010, one in crop residues and four on soybean fields. The expanding range in the distribution of E. heros in the Southern Hemisphere is believed to be due to the increased commercial trade among countries, increase in the area cultivated with soybean, and the adoption of no-tillage cropping systems.

Survivorship and reproductive performance of the pentatomids Euschistus heros (F.) (EH), Nezara viridula (L.) (NV), and Dichelops melacanthus (Dallas) (DM) were tested in the laboratory. A mixture of natural foods (pods of green beans, Phaseolus vulgaris, raw shelled peanuts, Arachis hypogaea, and fruits of privet, Ligustrum lucidum, and 50 pairs/box (25 x 20 x 20 cm) were used, observed for 30 days, and replicated three times. Thirty days after emergence, mean female survivorship was 91% (EH), 60% (NV), and 30% (DM). More egg masses were deposited during 11-20 days after emergence, with mean number of 45.1 (EH), 5.3 (NV), and 11.8 (DM). These values were smaller during the first 10 days (25.5, 2.1, and 4.7) and last 10 days (21-30 days) (39.4, 3.9, and 4.9), respectively. Mean maximum number of eggs/day was 489 (EH) on day 29, 474 (NV) on day 11, and 153 (DM) on day 14. Mean monthly fecundity (egg masses/box) was 985 (EH), 92 (NV), and 193 (DM), and mean number of eggs/box was 8,480; 5,147, and 2,042.7, respectively.

OBJETIVO: Avaliar os efeitos da administração oral de GLN sobre o estresse oxidativo em mulheres com câncer mamário submetidas à quimioterapia neoadjuvante com esquema FAC (5 fluouracil 500 mg/m2+doxorrubicina 50 mg/m2+ciclofosfamida 500 mg/m2 de superfície corporal). MÉTODOS: Vinte mulheres (idade média: 51,7 anos) com carcinoma ductal de mama, classificado como T3 ou T4 foram incluídas no estudo, independente do seu estado menstrual. Embalagens contendo 15g de glutamina ou proteína do leite foram preparadas por farmacêutico. Alocação dos pacientes foi feita na seqüência gerada por "software". Pacientes que receberam embalagens tipo "A" foram incluídas no grupo G1. Pacientes tratadas com a preparação denominada "B", foram incluídas no grupo G2. O material foi misturado com uso de liquidificador em 150 ml de água potável, e administrado diariamente aos pacientes durante todo o curso da quimioterapia neoadjuvante (esquema FAC). Amostras de sangue periférico foram coletadas no inicio dos três ciclos de quimioterapia, antes da infusão de drogas. Amostras de tumor e tecido mamário normal foram colhidas no final do procedimento cirúrgico (cirurgia de Patey). As amostras foram analisadas para determinação das concentrações de GSH e TBARS. RESULTADOS: Concentrações de TBARS/ GSH não foram diferentes no tumor. tecido mamário ou sangue, comparando os grupos G-2 vs.G-1. Além disso, não foram encontradas diferenças significativas nos níveis de TBARS e GSH comparando momentos diferentes dentro do mesmo grupo. CONCLUSÃO: GLN (15g/kg/dia) administrada por via oral não oferece proteção contra o estresse oxidativo sistêmico ou local em mulheres com câncer de mama, submetidas à quimioterapia neoadjuvante (FAC).

PURPOSE: To evaluate the effects of oral administration of GLN on the oxidative stress in women with breast cancer undergoing neoadjuvant FAC chemotherapy (5 fluouracil 500 mg/m²+Doxorubicin 50 mg/m²+Cyclophosphamide 500 mg/m² body surface area). METHODS: Twenty women (mean age: 51.7 years) with breast ductal carcinomas classified as T3 or T4 were included in the study, regardless of pre or post menopause status. Sachets containing glutamine 15g ("A") or milk protein 15g ("B") were prepared by a registered pharmacist. Allocation of patients was made by software program. Patients who received sachets labeled "A" were included in G1 group. The remaining patients, treated with the preparation labeled "B", were included in group G2. Sachets contents were blended in 150 ml of drinking water, and were given daily to each patient during the entire course of neoadjuvant chemotherapy. Peripheral blood samples were collected in the first day of each of the three cycles of chemotherapy before drug infusion. Tumor and normal breast samples were collected at the end of Patey´s surgical procedure. Samples were analysed for GSH and TBARS contents. RESULTS: TBARS and GSH values were not different in breast healthy and tumor tissues nor blood when comparing control (G-2) and glutamine-treated (G-1) patients. Also, no significant differences were found in TBARS and GSH levels comparing different timepoints within the same group. CONCLUSION: Oral GLN (15g/kg/day) offers no protection against systemic or local oxidative stress in women with breast Ca undergoing neoadjuvant chemotherapy (FAC).